Basel, Switzerland

Matilde Piras

This inventor holds 1 USPTO granted patent and 3 published patent applications and 3 EPO patents. Top assignee: Hoffmann-La Roche Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Matilde Piras. Retrieved from https://idiyas.com/inventor/matilde-piras

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Matilde Piras - Innovator in Medicinal Chemistry

Introduction

Matilde Piras is a talented inventor based in Basel, Switzerland. She is currently associated with F. Hoffmann-La Roche AG, a leading global healthcare company. Matilde has made significant contributions to the field of medicinal chemistry, focusing on the development of innovative compounds.

Latest Patent Applications

Matilde Piras has filed several patent applications, including:

1. **PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES** - This invention relates to a compound of formula (I) wherein R-R and A-A are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

2. **NEW THIAZOLOPYRIMIDINONE DERIVATIVES** - This invention also pertains to a compound of formula (I) wherein R-R and A-A are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Conclusion

Matilde Piras is an innovative inventor whose work in medicinal chemistry holds promise for future advancements in healthcare. Her latest patent applications reflect her commitment to developing new therapeutic compounds.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…